Leslie Leinwand, PhD
CSO, Biofrontiers Institute, CU Boulder
Co-Founder of Myogen
Michael Bristow, MD PhD
Professor of Medicine-Cardiology CU Anschutz
Co-founder of Myogen
Michael R. Bristow, MD, PhD, is currently Professor of Medicine (Cardiology) at the University of Colorado, Anschutz Medical Center in Aurora, CO. He is a fellow of the American College of Cardiology, a founding member of the Heart Failure Society of America, and a member of many other professional societies and editorial boards. Dr. Bristow has authored over 400 peer reviewed papers and chapters on heart failure and other cardiovascular diseases, was instrumental in elucidating key molecular mechanisms underlying heart failure and the use of β‐blockers for its treatment, has identified and characterized numerous genetic polymorphisms that affect cardiovascular drug action, and and is currently engaged in the development of pharmacogenetically targeted cardiovascular drugs such as bucindolol (Gencaro™). He has received many academic and industry honors, including the Therapeutics Frontiers Award by the American college of Clinical Pharmacy for developing -blockade as a treatment for heart failure, the Pharmaceutical Research and Manufacturers of America Clinical Trial Exceptional Service Award for the development of carvedilol (Coreg™) for heart failure, the Lifetime Achievement Award by the Heart Failure Society of America, and Scientist of the Year (2008) by the Colorado Chapter of the ARCS Foundation. Dr. Bristow is the President and CEO of ARCA biopharma, a Broomfield, CO company he founded in 2003 with the mission of developing genetically targeted therapies for heart failure and other cardiovascular diseases. In 2007 he co‐founded Miragen Therapeutics, Inc., a Boulder, CO company dedicated to utilizing the biologic properties of microRNA in developing therapies for cardiovascular diseases. He was also the principal founder and former chief science and medical officer of Myogen, Inc., a Westminster, CO biopharmaceutical company that was acquired by Gilead Sciences, Inc., in 2006.